Home Cart Sign in  
Chemical Structure| 1883863-52-2 Chemical Structure| 1883863-52-2

Structure of dBET57
CAS No.: 1883863-52-2

Chemical Structure| 1883863-52-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

dBET57 is a BRD4 heterobifunctional small-molecule ligand (PROTAC), exhibits significant and selective degradation of BRD4 BD1 (DC50/5h=500 nM), but is inactive on BRD4 BD2.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of dBET57

CAS No. :1883863-52-2
Formula : C34H31ClN8O5S
M.W : 699.18
SMILES Code : O=C(NCCNC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O)C[C@H]4C5=NN=C(C)N5C6=C(C(C)=C(C)S6)C(C7=CC=C(Cl)C=C7)=N4
MDL No. :MFCD32174278
InChI Key :CZRLOIDJCMKJHE-UXMRNZNESA-N
Pubchem ID :118912822

Safety of dBET57

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of dBET57

epigenetics

Isoform Comparison

Biological Activity

Target
  • BET

    BRD4BD1, DC50:500 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
SH-SY5Y 414 nM (IC50) 72 h To evaluate the effect of dBET57 on NB cell proliferation, results showed dBET57 inhibited NB cell proliferation in a dose-dependent manner J Immunol Res. 2022 Nov 16;2022:7945884
IMR-32 299 nM (IC50) 72 h To evaluate the effect of dBET57 on NB cell proliferation, results showed dBET57 inhibited NB cell proliferation in a dose-dependent manner J Immunol Res. 2022 Nov 16;2022:7945884
SK-N-BE(2) 643.4 nM (IC50) 72 h To evaluate the effect of dBET57 on NB cell proliferation, results showed dBET57 inhibited NB cell proliferation in a dose-dependent manner J Immunol Res. 2022 Nov 16;2022:7945884
CT26 cells Gradient concentrations To evaluate the effect of dBET57 on lactate levels, results showed that dBET57 significantly reduced lactate levels in the culture medium. Adv Sci (Weinh). 2024 Apr;11(15):e2309204
CT26 cells Gradient concentrations To evaluate the inhibitory effect of dBET57 on PD-L1 and c-Myc transcription, results showed that dBET57 inhibited the expressions of PD-L1 and c-Myc by degrading BRD4. Adv Sci (Weinh). 2024 Apr;11(15):e2309204
CT26 cells 1.4 mg/L To evaluate the degradation efficiency of dBET57 on BRD4 protein, results showed that nearly 70.5% of BRD4 protein was depleted at 1.4 mg L−1. Adv Sci (Weinh). 2024 Apr;11(15):e2309204

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice SK-N-BE(2) xenograft model Intraperitoneal injection 7.5 mg/kg Once daily for 21 days To evaluate the antitumor ability and safety of dBET57 in vivo, results showed dBET57 significantly inhibited tumor growth J Immunol Res. 2022 Nov 16;2022:7945884
BALB/c mice CT26 tumor model Intravenous injection 2 mg/kg Every two days for a total of five times To evaluate the inhibitory effect of dBET57 on tumor growth, results showed that DdLD NPs significantly suppressed tumor growth and reduced tumor weight. Adv Sci (Weinh). 2024 Apr;11(15):e2309204

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.43mL

0.29mL

0.14mL

7.15mL

1.43mL

0.72mL

14.30mL

2.86mL

1.43mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories